The new share buyback program comes in addition to the $6.4 billion remaining under current authorization.
The quarterly dividend was raised from 32 cents to 34 cents per share, which equates to an annual dividend of $1.36 per share. The increased dividend will be payable to shareholders Mar. 1, 2018.
More articles on supply chain:
FDA cracks down on homeopathic drugs
Teva Pharmaceuticals to cut more than 25% of workforce, consolidate US sites
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients
